{"title":"Pantoprazole 40 Mg Injection","description":"\u003cp\u003ePantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of\u003cspan\u003e \u003c\/span\u003e\u003cem\u003eH. pylori\u003c\/em\u003e\u003cspan\u003e \u003c\/span\u003einfections along with other antibiotics including\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/go.drugbank.com\/drugs\/DB01060\"\u003eamoxicillin\u003c\/a\u003e,\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/go.drugbank.com\/drugs\/DB01211\"\u003eclarithromycin\u003c\/a\u003e, and\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/go.drugbank.com\/drugs\/DB00916\"\u003emetronidazole\u003c\/a\u003e, for example.\u003csup class=\"text-reference-group\"\u003e\u003ca class=\"reference-popover-link\" data-content=\"Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK: The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016 Jul;151(1):51-69.e14. doi: 10.1053\/j.gastro.2016.04.006. Epub 2016 Apr 19. (PubMed ID 27102658)\" href=\"https:\/\/go.drugbank.com\/drugs\/DB00213#reference-A177271\" data-original-title=\"\" title=\"\"\u003e10\u003c\/a\u003e\u003c\/sup\u003e\u003csup class=\"text-reference-group\"\u003e\u003ca class=\"reference-popover-link\" data-content=\"TOP Guidelines - H pylori\" href=\"https:\/\/go.drugbank.com\/drugs\/DB00213#reference-F4498\" data-original-title=\"\" title=\"\"\u003e23\u003c\/a\u003e\u003c\/sup\u003e\u003cspan\u003e \u003c\/span\u003eIts efficacy is considered similar to other medications within the PPI class including\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/go.drugbank.com\/drugs\/DB00338\"\u003eomeprazole\u003c\/a\u003e,\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/go.drugbank.com\/drugs\/DB00736\"\u003eesomeprazole\u003c\/a\u003e,\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/go.drugbank.com\/drugs\/DB00448\"\u003elansoprazole\u003c\/a\u003e,\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/go.drugbank.com\/drugs\/DB05351\"\u003edexlansoprazole\u003c\/a\u003e, and\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/go.drugbank.com\/drugs\/DB01129\"\u003erabeprazole\u003c\/a\u003e.\u003c\/p\u003e\n\u003cp\u003ePantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme at the secretory surface of gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. As the binding of pantoprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, pantoprazole's duration of antisecretory effect persists longer than 24 hours.\u003csup class=\"text-reference-group\"\u003e\u003ca class=\"reference-popover-link\" data-content=\"Official drug label\" href=\"https:\/\/go.drugbank.com\/drugs\/DB00213#label-reference\" data-original-title=\"\" title=\"\"\u003eLabel\u003c\/a\u003e\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003eDue to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread. Long term use of PPIs such as pantoprazole have been associated with possible adverse effects, however, including increased susceptibility to bacterial infections (including gastrointestinal\u003cspan\u003e \u003c\/span\u003e\u003cem\u003eC. difficile\u003c\/em\u003e), reduced absorption of micronutrients including iron and B12, and an increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life.\u003csup class=\"text-reference-group\"\u003e\u003ca class=\"reference-popover-link\" data-content=\"Haastrup PF, Thompson W, Sondergaard J, Jarbol DE: Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol. 2018 Aug;123(2):114-121. doi: 10.1111\/bcpt.13023. Epub 2018 May 24. (PubMed ID 29658189)\" href=\"https:\/\/go.drugbank.com\/drugs\/DB00213#reference-A177571\" data-original-title=\"\" title=\"\"\u003e12\u003c\/a\u003e\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003ePPIs such as pantoprazole have also been shown to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme necessary for cardiovascular health. DDAH inhibition causes a consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginie (ADMA), which is thought to cause the association of PPIs with increased risk of cardiovascular events in patients with unstable coronary syndromes.\u003csup class=\"text-reference-group\"\u003e\u003ca class=\"reference-popover-link\" data-content=\"Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, Leiper J, Cooke JP: Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013 Aug 20;128(8):845-53. doi: 10.1161\/CIRCULATIONAHA.113.003602. Epub 2013 Jul 3. (PubMed ID 23825361)\" href=\"https:\/\/go.drugbank.com\/drugs\/DB00213#reference-A177577\" data-original-title=\"\" title=\"\"\u003e14\u003c\/a\u003e,\u003ca class=\"reference-popover-link\" data-content=\"Tommasi S, Elliot DJ, Hulin JA, Lewis BC, McEvoy M, Mangoni AA: Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance. Sci Rep. 2017 Jun 6;7(1):2871. doi: 10.1038\/s41598-017-03069-1. (PubMed ID 28588208)\" href=\"https:\/\/go.drugbank.com\/drugs\/DB00213#reference-A177580\" data-original-title=\"\" title=\"\"\u003e15\u003c\/a\u003e\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003ePantoprazole doses should be slowly lowered, or tapered, before discontinuing as rapid discontinuation of PPIs such as pantoprazole may cause a rebound effect and a short term increase in hypersecretion.\u003csup class=\"text-reference-group\"\u003e\u003ca class=\"reference-popover-link\" data-content=\"Reimer C, Sondergaard B, Hilsted L, Bytzer P: Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009 Jul;137(1):80-7, 87.e1. doi: 10.1053\/j.gastro.2009.03.058. Epub 2009 Apr 10. (PubMed ID 19362552)\" href=\"https:\/\/go.drugbank.com\/drugs\/DB00213#reference-A177574\" data-original-title=\"\" title=\"\"\u003e13\u003c\/a\u003e\u003c\/sup\u003e\u003c\/p\u003e","products":[],"url":"https:\/\/checkout.suryameds.com\/collections\/pantoprazole-40-mg-injection.oembed","provider":"SURYA MEDS","version":"1.0","type":"link"}